RESIDUAL BODIES ACTIVATE SERTOLI-CELL INTERLEUKIN-1-ALPHA (IL-1-ALPHA) RELEASE, WHICH TRIGGERS IL-6 PRODUCTION BY AN AUTOCRINE MECHANISM, THROUGH THE LIPOXYGENASE PATHWAY

被引:96
作者
SYED, V
STEPHAN, JP
GERARD, N
LEGRAND, A
PARVINEN, M
BARDIN, CW
JEGOU, B
机构
[1] UNIV RENNES 1, INSERM, U435, ETUD REPROD & MALE GRP, F-35042 RENNES, FRANCE
[2] FAC SCI PHARMACEUT & BIOL, PHARMACODYNAM LAB, F-35043 RENNES, FRANCE
[3] TURKU UNIV, DEPT ANAT, SF-20520 TURKU, FINLAND
[4] POPULAT COUNCIL, NEW YORK, NY 10021 USA
关键词
D O I
10.1210/en.136.7.3070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interleukin-1 (IL-1) and IL-6 are produced by Sertoli cells. As IL-1 stimulates IL-6 production in some tissues, the cascade of events that results in IL-6 secretion by Sertoli cells was studied. The addition of IL-1 alpha to Sertoli cells resulted in a time-dependent increase in IL-6 secretion. Incubation of Sertoli cells with two known stimulators of IL-1 production, lipopolysaccharide (LPS) and residual bodies, resulted in a significant increase in IL-1 release into the medium several hours before IL-6 release. That IL-1 is essential for IL-6 production from Sertoli cells was established by blocking the actions of LPS and residual bodies with an anti-IL-1 alpha antibody. An increase in the release of IL-1 before IL-6 was also observed in medium obtained from staged segments of intact seminiferous tubules; IL-1 reached a maximum level at stage VIII, when mature spermatozoa are released and residual bodies are formed and phagocytosed. The secretion of IL-6 was low during this stage and then increased progressively from stage IX onward, consistent with IL-1 stimulation of IL-6. The pathway of IL-1 alpha-induced release of IL-6 was studied in the presence of agents that influence arachidonic acid release and metabolism. IL-1 alpha was found to stimulate arachidonic acid release by Sertoli cells. Furthermore, a phospholipase A(2) inhibitor, aristolochic acid, significantly decreased IL-1-, LPS-, and pyrularia pubera thionin-induced IL-6 secretion from Sertoli cells. Indomethacin, a specific inhibitor of the cyclooxygenase pathway, had no significant effect on basal, but enhanced IL-1- and LPS-stimulated IL-6 production. The involvement of arachidonic acid metabolites produced in the Lipoxygenase pathway on the release of IL-6 was investigated indirectly, using nordihydroguaiaretic acid. This inhibitor reduced basal and IL-1 alpha- and LPS-stimulated IL-6 production. Ethacrynic acid, an inhibitor of peptidoleukotriene synthesis, also reduced basal IL-6 levels and blocked IL-1 alpha- as well as LPS-induced IL-6 secretion. It is concluded that IL-1 produced by Sertoli cells in response to LPS or residual bodies induces IL-6 through the lipoxygenase pathway.
引用
收藏
页码:3070 / 3078
页数:9
相关论文
共 50 条
  • [1] BALLOU LR, 1992, J BIOL CHEM, V267, P20044
  • [2] INTERLEUKIN-6 PRODUCTION BY THE BLAST CELLS OF ACUTE MYELOBLASTIC-LEUKEMIA - REGULATION BY ENDOGENOUS INTERLEUKIN-1 AND BIOLOGICAL IMPLICATIONS
    BEAUCHEMIN, V
    VILLENEUVE, L
    RODRIGUEZCIMADEVILLA, JC
    RAJOTTE, D
    KENNEY, JS
    CLARK, SC
    HOANG, T
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 1991, 148 (03) : 353 - 361
  • [3] BELLVE AR, 1989, J REPROD FERTIL, V85, P771, DOI 10.1530/jrf.0.0850771
  • [4] BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
  • [5] INTERLEUKIN-1 STIMULATES PROSTACYCLIN PRODUCTION BY CULTURED HUMAN-ENDOTHELIAL CELLS BY INCREASING ARACHIDONIC-ACID MOBILIZATION AND CONVERSION
    BREVIARIO, F
    PROSERPIO, P
    BERTOCCHI, F
    LAMPUGNANI, MG
    MANTOVANI, A
    DEJANA, E
    [J]. ARTERIOSCLEROSIS, 1990, 10 (01): : 129 - 134
  • [6] CHANG J, 1986, J IMMUNOL, V136, P1283
  • [7] CLERMONT Y., 1959, ARCH ANAT MICROSC ET MORPHOL EXPTL, V48, P37
  • [8] CROWL RM, 1991, J BIOL CHEM, V266, P2647
  • [9] HUMAN RECOMBINANT INTERLEUKIN-1 STIMULATES COLLAGENASE AND PROSTAGLANDIN E-2 PRODUCTION BY HUMAN SYNOVIAL-CELLS
    DAYER, JM
    DEROCHEMONTEIX, B
    BURRUS, B
    DEMCZUK, S
    DINARELLO, CA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (02) : 645 - 648
  • [10] DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]